1. Home
  2. SUZ vs ITCI Comparison

SUZ vs ITCI Comparison

Compare SUZ & ITCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SUZ
  • ITCI
  • Stock Information
  • Founded
  • SUZ 1924
  • ITCI 2002
  • Country
  • SUZ Brazil
  • ITCI United States
  • Employees
  • SUZ N/A
  • ITCI N/A
  • Industry
  • SUZ Paper
  • ITCI Biotechnology: Pharmaceutical Preparations
  • Sector
  • SUZ Basic Materials
  • ITCI Health Care
  • Exchange
  • SUZ Nasdaq
  • ITCI Nasdaq
  • Market Cap
  • SUZ N/A
  • ITCI 13.5B
  • IPO Year
  • SUZ N/A
  • ITCI N/A
  • Fundamental
  • Price
  • SUZ $9.11
  • ITCI $131.87
  • Analyst Decision
  • SUZ
  • ITCI Buy
  • Analyst Count
  • SUZ 0
  • ITCI 13
  • Target Price
  • SUZ N/A
  • ITCI $106.75
  • AVG Volume (30 Days)
  • SUZ 1.8M
  • ITCI 2.3M
  • Earning Date
  • SUZ 05-08-2025
  • ITCI 05-06-2025
  • Dividend Yield
  • SUZ 2.89%
  • ITCI N/A
  • EPS Growth
  • SUZ N/A
  • ITCI N/A
  • EPS
  • SUZ N/A
  • ITCI N/A
  • Revenue
  • SUZ $7,664,357,082.00
  • ITCI $680,852,000.00
  • Revenue This Year
  • SUZ $16.57
  • ITCI $41.92
  • Revenue Next Year
  • SUZ $9.26
  • ITCI $62.07
  • P/E Ratio
  • SUZ N/A
  • ITCI N/A
  • Revenue Growth
  • SUZ 19.24
  • ITCI 46.62
  • 52 Week Low
  • SUZ $8.78
  • ITCI $64.09
  • 52 Week High
  • SUZ $12.89
  • ITCI $131.98
  • Technical
  • Relative Strength Index (RSI)
  • SUZ 32.06
  • ITCI 84.55
  • Support Level
  • SUZ $9.21
  • ITCI $131.63
  • Resistance Level
  • SUZ $9.43
  • ITCI $131.98
  • Average True Range (ATR)
  • SUZ 0.16
  • ITCI 0.14
  • MACD
  • SUZ -0.01
  • ITCI -0.36
  • Stochastic Oscillator
  • SUZ 3.68
  • ITCI 85.13

About ITCI Intra-Cellular Therapies Inc.

Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.

Share on Social Networks: